Mankind Pharma Limited has issued a clarification to BSE Limited regarding the recent surge in trading volume of its shares, attributing the increase to prevailing market conditions while reaffirming its commitment to regulatory compliance.

BSE Inquiry and Company Response

The clarification came in response to a BSE email dated February 27, 2026, which sought explanation for the increased volume in Mankind Pharma's securities across exchanges. Company Secretary and Compliance Officer Hitesh Kumar Jain signed the response, addressing the exchange's concerns about the unusual trading activity.

Regulatory Compliance Confirmation

Mankind Pharma emphasized that it maintains prompt disclosure practices as specified under Part A of Schedule III of Regulation 30 of SEBI's Listing Obligations and Disclosure Requirements Regulations, 2015. The company stated it has not withheld any material information that could influence the price or volume behavior of its shares.

The pharmaceutical company clarified that the recent volume increase appears to be purely driven by market conditions, noting that it cannot comment specifically on such volume fluctuations. This response indicates the company's position that no undisclosed corporate developments or material events contributed to the trading surge.

Governance Standards

The company reiterated its commitment to maintaining the highest standards of governance and compliance norms. Mankind Pharma assured that it continues to make timely disclosures to stock exchanges under all applicable regulations, including Regulation 30 of the Listing Regulations.

The formal communication was digitally signed by Hitesh Kumar Jain on February 27, 2026, at 13:23:02 +05'30', demonstrating the company's prompt response to regulatory inquiries and adherence to digital documentation standards.

Mankind Pharma Limited has successfully won its appeal against a CGST penalty, with the Commissioner dropping a substantial penalty amount of INR 1,02,05,688. The pharmaceutical company informed the stock exchanges about this favorable regulatory development on February 26, 2026.

Appeal Order Details

The company received an order dated February 25, 2026, from the office of the Commissioner, CGST (Appeals), Meerut, Uttar Pradesh. This order was issued in response to the company's appeal filed against an earlier order passed by the Assistant Commissioner, Central Goods and Services Tax Act, Meerut, under Section 74 of the CGST Act, 2017.

Background and Timeline

The appeal was filed against an Order-in-Original dated December 27, 2024, which had imposed the penalty under Section 74 of the Central Goods and Services Tax Act, 2017. The company had previously informed the exchanges about this matter on December 28, 2024, and has now provided an update following the successful resolution of the appeal.

Regulatory Compliance

Mankind Pharma has fulfilled its disclosure obligations under Regulation 30 of the SEBI Listing Obligations and Disclosure Requirements Regulations, 2015. The company provided detailed information as required under the SEBI Master Circular No. HO/49/14/14(7)2025-CFD-POD2/I/3762/2026 dated January 30, 2026.

Impact Assessment

According to the company's disclosure, there is no quantifiable impact on the financial, operational, or other activities of the entity from this favorable order. The successful appeal represents a positive outcome for the pharmaceutical company, eliminating a significant penalty burden that was previously imposed.